TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19323633

Group type: EXPERIMENTAL
Intervention: 10 days of clindamycin or a first-generation cephalosporin (initially intravenously for the first 2-4 days)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 30 days of clindamycin or a first-generation cephalosporin (initially intravenously for the first 2-4 days)
Number of subjects: 130
Study: 16934042

Group type: EXPERIMENTAL
Intervention: Dobutamine 2.5 microg kg(‐1) min(‐1)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dobutamine 7.5 microg kg(‐1) min(‐1)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 15039684

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 10778243

Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Popular music
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study: 9471916

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (IT MTX) prophylaxis
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no CNS prophylaxis)
Number of subjects: 42
Study: 7682007

Group type: EXPERIMENTAL
Intervention: Light therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Psychopharmacological medication (withdrawn)
Number of subjects: 16
Study: 4036935

Group type: EXPERIMENTAL
Intervention: Aspirin (3 x 325 mg tablets)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ibuprofen (1 x 600 mg tablet)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (3 identical placebo tablets)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alcohol (3 ounces of 100 proof vodka diluted in 6 ounces of orange juice)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alcohol placebo (3 ounces of water diluted in orange juice)
Number of subjects: 60
Study: 30898632

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate cream (GTN)
Number of subjects: 100
Study: 28263383

Group type: EXPERIMENTAL
Intervention: MAP plus MC (n = 139)
Number of subjects: 422

Group type: COMPARATOR
Intervention: MAP alone (n = 157)
Number of subjects: 422
Study: 25724645

Group type: EXPERIMENTAL
Intervention: S-ketamine 0.25 mg/kg orally
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: S-ketamine 0.125 mg/kg intravenously
Number of subjects: 11
Study: 23245993

Group type: EXPERIMENTAL
Intervention: Short-acting β(2)-agonists (SABA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Muscarinic antagonists (SAMA)
Number of subjects: 32
Study: 21680723

Group type: EXPERIMENTAL
Intervention: Periodic computer-generated, evidence-based feedback based on questionnaire responses
Number of subjects: 465

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Comparison of intervention vs control
Number of subjects: 465
Study: 18573663

Group type: EXPERIMENTAL
Intervention: Permitting slight knee flexion
Number of subjects: 21

Group type: COMPARATOR
Intervention: Maintaining knee in total extension
Number of subjects: 21
Study: 15979655

Group type: EXPERIMENTAL
Intervention: Event-related potentials (ERPs) during a trial-by-trial task-switching version of the Stroop task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Working memory capacity measure
Number of subjects: 0
Study: 14688498

Group type: EXPERIMENTAL
Intervention: Combination therapy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiotensin receptor blockers
Number of subjects: 0
Study: 10364864

Group type: EXPERIMENTAL
Intervention: ondansetron (4 mg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: droperidol (1.25 mg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: metoclopramide (10 mg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 160
Study: 9133308

Group type: EXPERIMENTAL
Intervention: Thrombolysis with streptokinase 1.5 million IU plus oral aspirin 150 mg OD (n = 12)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (n = 9)
Number of subjects: 21
Study: 1991632

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound
Number of subjects: 52

Group type: COMPARATOR
Intervention: Computed tomography
Number of subjects: 52
Study: 6852623

Group type: EXPERIMENTAL
Intervention: D-penicillamine (600 mg/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (5 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: COMPARATOR
Intervention: No treatment after D-penicillamine or medroxyprogesterone
Number of subjects: 21
Study: 31377321

Group type: EXPERIMENTAL
Intervention: Pleasure-oriented messages
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Health-oriented messages
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (no leaflet)
Number of subjects: 198
Study: 30485297

Group type: EXPERIMENTAL
Intervention: Home-based, self-managed moderate intensity walking intervention for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 50
Study: 27189284

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneous dose
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 24589307

Group type: EXPERIMENTAL
Intervention: Intraperitoneal infusion of catumaxomab after complete resection of all macroscopic disease.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraperitoneal infusion of catumaxomab with different total doses administered in each of the 2 arms.
Number of subjects: 0
Study: 21546443

Group type: EXPERIMENTAL
Intervention: Zinc sulfate (10 mg elemental zinc)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 20973713

Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment for 12 weeks
Number of subjects: 168
Study: 17948207

Group type: EXPERIMENTAL
Intervention: Conventional weight loss treatment
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Obesity surgery (gastric banding)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Normal-weight individuals
Number of subjects: 251

Group type: COMPARATOR
Intervention: Obese individuals not participating in weight loss treatment
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Disordered eating patterns diagnosed after surgery
Number of subjects: 251
Study: 16262540

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM) intervention, 10-week duration, n = 31
Number of subjects: 49

Group type: COMPARATOR
Intervention: Modified wait-list control condition, n = 18
Number of subjects: 49
Study: 12003113

Group type: EXPERIMENTAL
Intervention: Case Management (CM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Case Management (No‐CM)
Number of subjects: 0
Study: 10601130

Group type: EXPERIMENTAL
Intervention: Thiol group alkylation with N-ethylmaleimide (NEM) in untreated erythrocytes from EHT-FH patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiol group alkylation with N-ethylmaleimide (NEM) in normal erythrocytes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated erythrocytes from EHT-FH patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal control erythrocytes
Number of subjects: 0
Study: 7860761

Group type: EXPERIMENTAL
Intervention: IDDM subjects
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 15
Study: 2010700

Group type: EXPERIMENTAL
Intervention: SAVAS technique
Number of subjects: 107

Group type: COMPARATOR
Intervention: Compression sclerotherapy (CS)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Dentist's technique (DT)
Number of subjects: 107
Study: 7200319

Group type: EXPERIMENTAL
Intervention: Lightly hydrogenated soy oil
Number of subjects: 24

Group type: COMPARATOR
Intervention: Corn oil
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unhydrogenated soy oil
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fat diets
Number of subjects: 24
Study: 30799396

Group type: EXPERIMENTAL
Intervention: Low-dose oral prednisolone for 3 days (PSL 3)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low-dose oral prednisolone for 7 days (PSL 7)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low-dose oral prednisolone (both groups)
Number of subjects: 44
Study: 27773929

Group type: EXPERIMENTAL
Intervention: Pomalidomide
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 26013187

Group type: EXPERIMENTAL
Intervention: febuxostat 80 mg/day
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: febuxostat 40 mg/day
Number of subjects: 504

Group type: COMPARATOR
Intervention: allopurinol 300 mg/day
Number of subjects: 504

Group type: COMPARATOR
Intervention: all groups
Number of subjects: 504
Study: 25411289

Group type: EXPERIMENTAL
Intervention: Orange maize (biofortified)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: VA+ (white maize with 400 μg retinol activity equivalents in oil)
Number of subjects: 140

Group type: COMPARATOR
Intervention: VA- (white maize with placebo oil)
Number of subjects: 140
Study: 22464779

Group type: EXPERIMENTAL
Intervention: LAM + ADV combination therapy
Number of subjects: 174

Group type: COMPARATOR
Intervention: LAM mono-therapy
Number of subjects: 174

Group type: COMPARATOR
Intervention: ADV mono-therapy
Number of subjects: 174
Study: 19387976

Group type: EXPERIMENTAL
Intervention: Time-delayed capsule formulation with 20% HPMC
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Time-delayed capsule formulation with 24% HPMC
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Time-delayed capsule formulation with 35% HPMC
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nondisintegrating riboflavin tablet (used in pulsed release study)
Number of subjects: 8
Study: 17320942

Group type: EXPERIMENTAL
Intervention: Audiovisual reminder function (AVRF)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no AVRF)
Number of subjects: 110
Study: 15330916

Group type: EXPERIMENTAL
Intervention: Duodenal bolus infusions of 5 ml of acid
Number of subjects: 22

Group type: COMPARATOR
Intervention: Duodenal bolus infusions of normal saline
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ondansetron (5‐HT(3) receptor antagonist)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 10738704

Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growth factors (basic fibroblast growth factor, transforming growth factor, platelet‐derived growth factor, epidermal growth factor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control cells (FR control)
Number of subjects: 0
Study: 9390746

Group type: EXPERIMENTAL
Intervention: Recombinant canarypox virus expressing gp160MN or recombinant gp160MN/LAI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prime-boost regimen using canarypox expressing gp160 followed by rgp160 boost
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Boost with V3 synthetic peptide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prime-boost regimen using canarypox recombinants expressing gp160 or gp120 and purified rgp160
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: V3 synthetic peptide boost
Number of subjects: 0
Study: 1607978

Group type: EXPERIMENTAL
Intervention: Epidural corticosteroids (40 mg methylprednisolone acetate)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 84
Study: 3982742

Group type: EXPERIMENTAL
Intervention: External cephalic version under tocolysis
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Successful external cephalic version
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Successful external cephalic version with vertex presentation
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (randomized)
Number of subjects: 148
Study: 3069500

Group type: EXPERIMENTAL
Intervention: Computerised test for assessment of PVD
Number of subjects: 200

Group type: COMPARATOR
Intervention: Skilled clinician diagnosis
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Modified computer protocol for non-vascular diagnosis
Number of subjects: 200
Study: 31127753

Group type: EXPERIMENTAL
Intervention: Maitland's oscillatory mobilization
Number of subjects: 46

Group type: COMPARATOR
Intervention: Kaltenborn's sustained stretch mobilization
Number of subjects: 46
Study: 30769056

Group type: EXPERIMENTAL
Intervention: Spot stenting
Number of subjects: 125

Group type: COMPARATOR
Intervention: Long stenting
Number of subjects: 125
Study: 28689524

Group type: EXPERIMENTAL
Intervention: Supervised Structured Aerobic Exercise Training (SSAET) program, routine medication, and dietary plan
Number of subjects: 102

Group type: COMPARATOR
Intervention: Routine medication and dietary plan
Number of subjects: 102
Study: 26386974

Group type: EXPERIMENTAL
Intervention: Recline Exercise (RE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Head Lift Exercise (HLE)
Number of subjects: 40
Study: 23393214

Group type: EXPERIMENTAL
Intervention: Group Medical Clinics (GMC)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 239
Study: 21165658

Group type: EXPERIMENTAL
Intervention: Local bone graft
Number of subjects: 82

Group type: COMPARATOR
Intervention: Iliac crest bone graft (ICBG)
Number of subjects: 82
Study: 18773134

Group type: EXPERIMENTAL
Intervention: Vaginal vault suspension after hysterectomy (n = 32)
Number of subjects: 6214

Group type: COMPARATOR
Intervention: Control group (n = 236)
Number of subjects: 6214

Group type: EXPERIMENTAL
Intervention: Preoperative prolapse
Number of subjects: 6214

Group type: EXPERIMENTAL
Intervention: Sexual activity
Number of subjects: 6214

Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy
Number of subjects: 6214
Study: 17575757

Group type: EXPERIMENTAL
Intervention: Fixation of the mesh (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No fixation of the mesh (Group B)
Number of subjects: 40
Study: 12950574

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gel (CG), coronally unsealed
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (CaOH2), coronally unsealed
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide + 2% chlorhexidine gel (CaOH2 + CG), coronally unsealed
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gel (CG) + coronal seal
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (CaOH2) + coronal seal
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide + 2% chlorhexidine gel (CG + CaOH2) + coronal seal
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: No intracanal medicament + coronal seal
Number of subjects: 80

Group type: COMPARATOR
Intervention: Positive control group (PC) - no treatment, coronally unsealed
Number of subjects: 80

Group type: COMPARATOR
Intervention: Negative control group (NC) - intact crowns
Number of subjects: 80
Study: 11023562

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS) with added parameter 'irregular tumor‐vessel relationship'
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS) parameters for portal venous involvement
Number of subjects: 75
Study: 8723171

Group type: EXPERIMENTAL
Intervention: Pranidipine 1 mg od
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Pranidipine 2 mg od
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Pranidipine 4 mg od
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Pranidipine 8 mg od
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 1362887

Group type: EXPERIMENTAL
Intervention: L-659,066 (8 mg administered by short intravenous infusion)
Number of subjects: 0
Study: 3907286

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants for one month
Number of subjects: 135

Group type: COMPARATOR
Intervention: Oral anticoagulants for six months
Number of subjects: 135
Study: 29069291

Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combination intervention
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 49
Study: 27676396

Group type: COMPARATOR
Intervention: 0 mg/d CAP from chili powder
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5 mg/d CAP from chili powder
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg/d CAP from chili powder
Number of subjects: 12
Study: 25362668

Group type: EXPERIMENTAL
Intervention: Mobility platform
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard equipment
Number of subjects: 71
Study: 22495998

Group type: EXPERIMENTAL
Intervention: Diabetic patients (type 2 diabetes)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 98
Study: 20538121

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 18575308

Group type: EXPERIMENTAL
Intervention: Pro Seal varnish applied before sealant
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pro Seal varnish applied after sealant
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (sealant only)
Number of subjects: 60
Study: 16019866

Group type: EXPERIMENTAL
Intervention: Training group (30 patients) trained 3 times a week during 3 months and once a week during 6 months.
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (13 patients)
Number of subjects: 43
Study: 12425363

Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A (btA) injection with conventional physical therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional physical therapy only
Number of subjects: 35
Study: 10771458

Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg once daily for 6 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8610920

Group type: EXPERIMENTAL
Intervention: Breast cancer treatment in black women
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breast cancer diagnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tumor biology
Number of subjects: 0
Study: 1356277

Group type: EXPERIMENTAL
Intervention: Alpidem (mean dose 112.5 mg daily)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Lorazepam (mean 3.5 mg daily)
Number of subjects: 23
Study: 3895962

Group type: EXPERIMENTAL
Intervention: Single-dose treatment with 500 mg clotrimazole vaginal tablet
Number of subjects: 115

Group type: COMPARATOR
Intervention: 3-day treatment with two 100 mg vaginal tablets administered daily
Number of subjects: 115
Study: 30430760

Group type: EXPERIMENTAL
Intervention: Endoscopic method
Number of subjects: 33

Group type: COMPARATOR
Intervention: Microscopic method
Number of subjects: 33
Study: 30008052

Group type: EXPERIMENTAL
Intervention: Co-Crystal of Tramadol-Celecoxib (CTC) under fed conditions
Number of subjects: 36

Group type: COMPARATOR
Intervention: Co-Crystal of Tramadol-Celecoxib (CTC) under fasting conditions
Number of subjects: 36
Study: 27081705

Group type: EXPERIMENTAL
Intervention: NeoHeal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study: 26160058

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 7) - integrated content on physical activity (PA) and sedentary behavior (SB) into health education (HE) lessons
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison group (n = 7) - standard HE lessons
Number of subjects: 14
Study: 22930241

Group type: EXPERIMENTAL
Intervention: BMD reports from reading specialists
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Research team assessment of fracture risk
Number of subjects: 48
Study: 20497921

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard support therapy (ST)
Number of subjects: 16
Study: 18305069

Group type: COMPARATOR
Intervention: Open suction (OS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Closed suction (CS)
Number of subjects: 30
Study: 16178478

Group type: EXPERIMENTAL
Intervention: Icodextrin (ID)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Amino acids (AA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Glucose-only-based solutions
Number of subjects: 22
Study: 12546607

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium, 75 mg twice daily
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Acetaminophen, 1000 mg 4 times daily
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 10485533

Group type: EXPERIMENTAL
Intervention: Disposable hydrogel lenses on a 6-night extended wear and replacement schedule
Number of subjects: 330
Study: 7561223

Group type: EXPERIMENTAL
Intervention: 8-hourly administration of controlled-release morphine (MS Contin)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 12-hourly administration of controlled-release morphine (MS Contin)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 8-hourly and 12-hourly administration of controlled-release morphine (MS Contin)
Number of subjects: 19
Study: 1782724

Group type: EXPERIMENTAL
Intervention: EPO
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (unchanged EPO prescription)
Number of subjects: 8
Study: 6907170

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31996580

Group type: EXPERIMENTAL
Intervention: Transvaginal repair
Number of subjects: 64

Group type: COMPARATOR
Intervention: Transperineal repair
Number of subjects: 64
Study: 31611496

Group type: EXPERIMENTAL
Intervention: Acidic solution, pH 1-2 (CS)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Distilled water, pH 6.9 (DW)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Alkaline solution, pH 10-11 (KS)
Number of subjects: 135
Study: 28597306

Group type: EXPERIMENTAL
Intervention: Etanercept-methotrexate combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-methotrexate combination therapy
Number of subjects: 0
Study: 25123447

Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 20